Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis

He, Qing-Yu; Liao, Banghua; Xiao, Kan; Zhou, Liang; Feng, Shijian; Li, Hong; Wang, Kun‐Jie

doi:10.1007/s11255-018-1982-y

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27,28 However, several studies, including a recent meta-analysis, conclude that the use of PDE5i for EF after RP is oncologically safe. 29 In addition, Korean population studies, including our institutional experience, support the safety of various PDE5i therapies in terms of their oncological outcomes after RP. 30 Several limitations of our study should be considered.…”

Section: Discussionmentioning

confidence: 73%

Efficacy and Safety of Combined Phosphodiesterase Type 5 Inhibitors as a Salvage Medical Treatment in Patients with Erectile Dysfunction after Nerve-Sparing Radical Prostatectomy

Lee

Chung

Kwon

et al. 2020

JOMH

View full text Add to dashboard Cite

PurposePenile rehabilitation therapy using phosphodiesterase type 5 inhibitors (PDE5i) is used widely as a first-line therapy in patients with erectile dysfunction (ED) after radical prostatectomy (RP). However, many patients undergoing such therapy still complain of inappropriate erectile function (EF). Therefore, we evaluated the efficacy and safety of combined PDE5i therapy as a salvage medical treatment in patients nonresponsive to initial penile rehabilitation using daily PDE5i after nerve-sparing RP. MethodsWe retrospectively reviewed 58 nonresponders (Erection Hardness Score [EHS] of 2 or less) to penile rehabilitation using tadalafil (5 mg) daily for more than 12 weeks and who subsequently received combined PDE5i therapy (tadalafil [5 mg] once daily with sildenafil [50 mg] or udenafil [100 mg] on demand). Success after combined therapy is defined by EHS scores of 3 or 4. Safety was assessed by observing drug tolerability and adverse events. ResultsOf the 58 patients, combined therapy was successful in 39.7% of cases. The mean preoperative International Index of Erectile Function (IIEF-5) score was significantly higher in the success group after combined

show abstract